{"entity":{"id":"march-biosciences","kind":"company","name":"March Biosciences","aka":["march.biosciences","March Biosciences Inc"],"tldr":"March Biosciences makes a CAR-T cell therapy aimed at the protein CD5 to treat T-cell lymphomas, blood cancers for which few targeted treatments exist.","summary":"March Biosciences Inc., based in Houston, Texas and co-founded by Sarah Hein, Maksim Mamonkin and Malcolm Brenner, develops CAR T cell therapies for haematological cancers, using an approach it says unlocks targets without additional gene editing. MB-105 is a CD5-directed CAR T cell therapy in a phase 2 trial in CD5-positive T-cell lymphoma (NCT06534060). Its first registered cancer trial, NCT06534060, was posted on ClinicalTrials.gov in August 2024.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://march.bio/"},{"label":"About and team","url":"https://march.bio/about/"}],"tags":[],"related":[],"cancers":["peripheral-t-cell-lymphoma"],"sections":["cell-therapy"],"technologies":["car-t"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06534060"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Company website read on 29 October 2026. Founding year not stated. No financing round was read. OnCo has no CD5 target record, so no target relation is made."],"hq":"Houston, TX","country":"US","companyType":"cell-therapy","website":"https://march.bio/","stage":"startup","investors":[],"funding":[]},"route":"/companies/march-biosciences/","neighbours":{"cancer":[{"id":"peripheral-t-cell-lymphoma","kind":"cancer","name":"Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)","route":"/cancers/peripheral-t-cell-lymphoma/"}],"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"trial":[{"id":"nct06534060","kind":"trial","name":"MB-105 in Patients With CD5 Positive T-cell Lymphoma","route":"/trials/nct06534060/"}]}}